MARTY DACK: Open Payments
NPI 1871686337 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,103 in 37 payments from 16 companies in 2025. Trend: 2023 $651 · 2024 $783 · 2025 $1,103
Food & beverage: $1,102Education: $2
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 6 | $185 |
| Novartis Pharmaceuticals Corporation | 4 | $176 |
| Calliditas Therapeutics US Inc. | 4 | $136 |
| Amgen Inc. | 6 | $108 |
| AstraZeneca Pharmaceuticals LP | 1 | $104 |
| AKEBIA THERAPEUTICS INC | 2 | $81 |
| Apellis Pharmaceuticals, Inc. | 3 | $76 |
| Fresenius USA Marketing, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
Products named: TARPEYO, AIRSUPRA, Fabhalta, TAVNEOS, Vanrafia, Vafseo, Empaveli, VELPHORO.
Industry payments across MI — which companies pay providers there.
